ReviewMetabolites2021
Metabolomics-Microbiome Crosstalk in the Breast Cancer Microenvironment.
Review in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human gut, breast, and oral microbiome in breast cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- The Human Breast Microbiome: From Homeostasis to Malignancy, Mechanistic Insights and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- NMR-based metabolomics analysis in breast cancer patients from Saudi Arabia: a pilot study.Scientific reports · 2026Article
- Breast-Cancer-Derived Secretomes from MCF-7 Cells Modulate Bacterial Pathogenic Traits.International journal of molecular sciences · 2026Article
- From gut to mouth: salivary signatures of carcinogenic microbiota.Frontiers in cellular and infection microbiology · 2026Review
- The role of gut microbiota in breast cancer: biomarker identification and therapeutic applications.Antonie van Leeuwenhoek · 2025Review
- Metagenomic analyses reveal E. coli-derived siderophores as potential signatures for breast cancer.Journal of translational medicine · 2025Article
- The role of NETosis in breast cancer: mechanistic insights and biomarker potential.Breast cancer research : BCR · 2025Review
- From lab to life: technological innovations in transforming cancer metastasis detection and therapy.Discover oncology · 2025Review
- The MDA-MB-231 Breast Cancer Cell Secretomes Modify Metabolomes ofInternational journal of molecular sciences · 2025Article
- Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Tumor-infiltrating immune cells state-implications for various breast cancer subtypes.Frontiers in immunology · 2025Review
- Intratumoral microbial abundance and load influence the immune microenvironment of oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- Urinary and oral microbiota in Polish women: a pilot case-control study of breast cancer.Frontiers in microbiology · 2025Article
- Comparative Analysis of Breast Cancer Metabolomes Highlights Fascin's Central Role in Regulating Key Pathways Related to Disease Progression.International journal of molecular sciences · 2024Article
- The role of microbiota in tumorigenesis, progression and treatment of bladder cancer.Microbiome research reports · 2024Review
- Bibliometric analysis of global research trends between gut microbiota and breast cancer: from 2013 to 2023.Frontiers in microbiology · 2024Article
- Exploring the human microbiome - A step forward for precision medicine in breast cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- Proteomics Investigation of the Impact of theInternational journal of molecular sciences · 2023Article
- Exploring breast tissue microbial composition and the association with breast cancer risk factors.Breast cancer research : BCR · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer, the most frequent cancer diagnosed among females, is associated with a high mortality rate worldwide. Alterations in the microbiota have been linked with breast cancer development, suggesting the possibility of discovering disease biomarkers. Metabolomics has emerged as an advanced promising analytical approach for profiling metabolic features associated with breast cancer subtypes, disease progression, and response to treatment. The microenvironment compromises non-cancerous cells such as fibroblasts and influences cancer progression with apparent phenotypes. This review discusses the role of metabolomics in studying metabolic dysregulation in breast cancer caused by the effect of the tumor microenvironment on multiple cells such as immune cells, fibroblasts, adipocytes, etc. Breast tumor cells have a unique metabolic profile through the elevation of glycolysis and the tricarboxylic acid cycle metabolism. This metabolic profile is highly sensitive to microbiota activity in the breast tissue microenvironment. Metabolomics shows great potential as a tool for monitoring metabolic dysregulation in tissue and associating the findings with microbiome expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.